Begin with the Exit in Mind

Steps to Value Creation


Making a larger number of small investments in early stage companies and exiting early via acquisition or merger offers the best balance of risk & return in medical technology.

Focus

Epic BioVentures focuses on early to mid-stage medical device, biotechnology, diagnostic, and pharmaceutical companies. Target companies are expected to have:

  • Modest capital requirements;
  • Preferred exit strategy by acquisition or by merger with a corporate partner;
  • Exit timing of three to five years, often before pivotal clinical trials or market launch

We believe that making a larger number of small investments in early stage companies and exiting early via acquisition or merger offers the best balance of risk and return in medical technology. An early exit prior to undertaking pivotal clinical trials or market introduction should significantly reduce investment risk by removing regulatory and reimbursement obstacles from the equation as well as reduce or eliminate marketing expenses while offering sizable return on investment potential.